Drug intelligence / Profile preview

PHE1411

Development stage: Preclinical
Lead developer: Zhongke CELFULL

Overview

PHE1411 is an investigational therapeutic candidate being developed by Zhongke CELFULL Mitochondrial Medicine for the treatment of phenylketonuria (PKU). PKU is a rare genetic metabolic disorder characterized by a deficiency in the enzyme phenylalanine hydroxylase, which leads to the toxic accumulation of phenylalanine in the body. PHE1411 is currently in the preclinical stage of development. Although the developer focuses on mitochondrial medicine and metabolic health, specific details regarding the drug's modality (e.g., small molecule, enzyme replacement) or its exact molecular mechanism of action have not been publicly disclosed in the company's pipeline.

Beyond the preview

Go deeper on PHE1411.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHE1411.

Explore the full profile